{"id":389,"date":"2024-09-09T15:33:01","date_gmt":"2024-09-09T12:33:01","guid":{"rendered":"https:\/\/www.cagrioner.com\/tubitak\/?page_id=389"},"modified":"2024-10-03T12:41:00","modified_gmt":"2024-10-03T09:41:00","slug":"asi-ve-ilac-calismalari","status":"publish","type":"page","link":"https:\/\/covid19.tubitak.gov.tr\/en\/asi-ve-ilac-calismalari\/","title":{"rendered":"Vaccine and Drug Studies"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The platform has completed or terminated 12 out of the original 16 R&D studies, either because research objectives were achieved or because the candidate product was unsuitable.<\/p>

There are 4 ongoing studies:<\/p>

  • One is receiving non-IPA funding:\n-Virus-Like Particles (VLP) awaiting Phase IIB\/III approval<\/li>
  • 3 tanesi pilot \u00fcretim i\u00e7in haz\u0131r ve IPA’dan s\u00fcrekli deste\u011fe ihtiya\u00e7 duymaktad\u0131r.
    • DNA a\u015f\u0131s\u0131<\/li>
    • Rekombinant spike protein a\u015f\u0131s\u0131<\/li>
    • N\u00f6tralize Edici Antikorlar ilac\u0131<\/li><\/ul><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
      \n\t\t\t\t\t
      \n\t\t
      \n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Logo_Ege_Uni\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      V5 - DNA Vaccine<\/strong><\/p>

      Ege University<\/span><\/p>

      Total of 22 researchers including 11 women<\/span><\/p>

      \u00a0<\/p>

      Achievements<\/strong><\/p>

      DNA vaccine design<\/p>

      Development of DNA vaccine platform<\/p>

      Production optimization of developed DNA vaccine in bioreactor<\/p>

      GMP production approval obtained from TITCK for DNA vaccine production<\/p>

      \u00a0<\/p>

      Technical Capabilities<\/strong><\/p>

      Rapid DNA vaccine creation in FDA-approved vector<\/p>

      DNA vaccine application using electroporation method to increase vaccine efficacy<\/p>

      Upstream and downstream process optimization<\/p>

      \u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

      \n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"izmir\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      V2 - Recombinant spike protein vaccine<\/strong><\/p>

      Izmir Biomedicine and Genome Center<\/span><\/p>

      Total of 35 researchers including 17 women<\/span><\/p>

      \u00a0<\/p>

      Achievements<\/strong><\/p>

      RBD-expressing yeast strain was developed<\/p>

      Animal studies were completed<\/p>

      Technology transfer to industry was completed<\/p>

      \u00a0<\/p>

      Technical Capabilities<\/strong><\/p>

      Application of Genetic Engineering techniques<\/p>

      Experience gained in yeast physiology, fermentation, purification and formulation<\/p>

      \u00a0<\/p>

      Scientific Outputs<\/strong><\/p>

      1 article was published<\/p>

      Technology transfer files including batch records were transferred to ATABAY BIO<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

      \n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"tubitak\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      Neutralizing Antibody Drug<\/strong><\/p>

      TUBITAK - MAM<\/span><\/p>

      Total of 50 researchers including 25 women<\/span><\/p>

      \u00a0<\/p>

      Achievements<\/strong><\/p>

      Pre-clinical and stability studies completed for drug neutralizing COVID-19<\/p>

      \u00a0<\/p>

      Technical Capabilities<\/strong><\/p>

      Recombinant antibody engineering<\/p>

      In vitro neutralization test development<\/em><\/p>

      In vivo challenge test<\/em><\/p>

      \u00a0<\/p>

      Scientific Outputs<\/strong><\/p>

      6 articles published<\/p>

      6 publication submissions made<\/p>

      1 review published<\/p>

      2 patent preparations<\/p>

      10 posters<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

      Platform, orijinal 16 Ar-Ge \u00e7al\u0131\u015fmas\u0131ndan 12’sini ya ara\u015ft\u0131rma hedeflerine ula\u015f\u0131ld\u0131\u011f\u0131 i\u00e7in ya da aday \u00fcr\u00fcn uygun olmad\u0131\u011f\u0131 i\u00e7in tamamlam\u0131\u015f veya sonland\u0131rm\u0131\u015ft\u0131r. 4 devam eden \u00e7al\u0131\u015fma bulunmaktad\u0131r: 1 tanesi IPA d\u0131\u015f\u0131 finansman almaktad\u0131r: -Vir\u00fcs Benzeri Par\u00e7ac\u0131klar (VLP) Faz IIB\/III onay\u0131 beklemektedir 3 tanesi pilot \u00fcretim i\u00e7in haz\u0131r ve IPA’dan s\u00fcrekli deste\u011fe ihtiya\u00e7 duymaktad\u0131r. DNA a\u015f\u0131s\u0131 Rekombinant […]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-389","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/pages\/389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/comments?post=389"}],"version-history":[{"count":10,"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/pages\/389\/revisions"}],"predecessor-version":[{"id":691,"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/pages\/389\/revisions\/691"}],"wp:attachment":[{"href":"https:\/\/covid19.tubitak.gov.tr\/en\/wp-json\/wp\/v2\/media?parent=389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}